logo
  

Olaplex CFO Eric Tiziani To Step Down; Reaffirms Q1 Net Sales Guidance

Olaplex Holdings Inc. (OLPX) said that Eric Tiziani will step down as Chief Financial Officer to pursue another opportunity, effective May 3. Paul Kosturos, a seasoned financial executive with over 30 years of experience, will join Olaplex and serve as Interim CFO following Tiziani's departure.

The company noted that it has launched an external search for a new Chief Financial Officer in partnership with a leading executive search firm.

In addition, Olaplex reaffirmed its guidance for net sales for the first quarter of 2024 in the range of $92 million to $97 million. Analysts polled by Thomson Reuters expected the company to report revenues of $95.3 million for the first quarter. Analysts' estimates typically exclude special items.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Automajor General Motors plans to end production of its gasoline-powered Chevrolet Malibu car later this year as it prepares to produce new electric vehicles, reports said. Chevy Malibu, which was launched in 1964, has since been sold more than 10 million in numbers. The Malibu will end its production in November. Ride-hailing and delivery platform Uber Technologies, Inc. (UBER) reported Wednesday a net loss for the first quarter that sharply widened from last year, hurt by a huge net unrealized loss related to the revaluation of Uber's equity investments. Loss per share for the quarter missed analysts' expectations, while quarterly revenues topped it. Shares of Siemens Energy AG were gaining more than 12 percent in German trading after the company on Wednesday raised its outlook for fiscal 2024 after reporting a profit in its second quarter, compared to last year's loss, amid positive market environment. Meanwhile, second-quarter orders were lower than last year, and the company maintained annual earnings forecast.

This week, we feature J&J’s Talc litigation closure,Emergent’s strategic changes for growth ,Pfizer’s breakthrough hemophilia B gene therapy approval,Novartis’s strategic Mariana Oncology Buyout, and Beyfortus Breakthrough RSV prevention.

View More Videos
RELATED NEWS
Follow RTT